Integrated Filing — IndAS



General information about company

Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 12-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment The Company is exclusively engaged in pharmaceutical business
Start date and time of board meeting 12-11-2026   11:30:00
End date and time of board meeting 12-11-2026   13:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 13-02-2026
Indicate Company website link for updated RPT policy of the Company https://admin.alkemlabs.com/uploads/Related_Party_Transactions_Policy_1e79a77a4a.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No defaults on loan and debt securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,07,136.00 5,73,909.00
Other income 12,188.00 25,850.00
Total income 3,19,324.00 5,99,759.00
2 Expenses
(a) Cost of materials consumed 73,173.00 1,40,461.00
(b) Purchases of stock-in-trade 14,358.00 29,024.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (4,487.00) (10,836.00)
(d) Employee benefit expense 56,054.00 1,10,801.00
(e) Finance costs 1,471.00 3,223.00
(f) Depreciation, depletion and amortisation expense 5,857.00 11,579.00
(f) Other Expenses
1 Other expenses 68,883.00 1,31,650.00
Total other expenses 68,883.00 1,31,650.00
Total expenses 2,15,309.00 4,15,902.00
3 Total profit before exceptional items and tax 1,04,015.00 1,83,857.00
4 Exceptional items 3,500.00 3,500.00
5 Total profit before tax 1,07,515.00 1,87,357.00
6 Tax expense
7 Current tax 34,582.00 55,357.00
8 Deferred tax (3,315.00) (1,245.00)
9 Total tax expenses 31,267.00 54,112.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 76,248.00 1,33,245.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 76,248.00 1,33,245.00
17 Other comprehensive income net of taxes (255.00) (511.00)
18 Total Comprehensive Income for the period 75,993.00 1,32,734.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,391.00 2,391.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 63.77 111.44
Diluted earnings (loss) per share from continuing operations 63.77 111.44
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 63.77 111.44
Diluted earnings (loss) per share from continuing and discontinued operations 63.77 111.44
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the Standalone Financial Results: 1. The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 11 November 2026 and subsequently approved by the Board of Directors at its meeting held on 12 November 2026. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2026. 3. The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company had executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited. During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. Key financial information of Discontinued Operations: Quarter ended 30.09.2026 Total Income : NIL Total expenses : NIL Profit before tax : NIL Total tax expense : NIL Net profit for the period : NIL Quarter ended 30.06.2026 Total Income : NIL Total expenses : NIL Profit before tax : NIL Total tax expense : NIL Net profit for the period : NIL Quarter ended 30.09.2025 Total Income : 5,622.8 Total expenses : 4,653.3 Profit before tax : 969.5 Total tax expense : 338.8 Net profit for the period : 630.7 Six months ended 30.09.2026 Total Income : NIL Total expenses : NIL Profit before tax : NIL Total tax expense : NIL Net profit for the period : NIL Six months ended 30.09.2025 Total Income : 9,181.0 Total expenses : 7,690.5 Profit before tax : 1,490.5 Total tax expense : 520.8 Net profit for the period : 969.7 Year ended 31.03.2026 Total Income : 9,181.0 Total expenses : 7,690.5 Profit before tax : 1,490.5 Total tax expense : 520.8 Net profit for the period : 969.7 Exceptional items include: a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of Rs. 350 million from a real estate investment made by the Parent Company, which was impaired during the quarter and year ended 31 March 2026. b) Exceptional item amounting to Rs.142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility by the Parent Company which was impaired earlier. c) Exceptional items include: a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of Rs. 350 million against investment made, which was impaired during the quarter and year ended 31 March 2026. b) Exceptional item amounting to Rs.142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility which was impaired earlier. c) Exceptional items amounting to Rs.1,430.9 million for the year ended 31 March 2026 is on account of - Impact of labour code of Rs. 826.8 million towards gratuity and leave encashment for past service cost. - Impairment of real estate investment made of Rs.747 million. - Gain on sale of Indore facility of Rs.142.9 million. 5. During the year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate as at 31 March 2026. Subsequently in the current period, the tax expense has been recognized based on the enacted tax rates applicable under the new regime. 6. The Company operates in one reportable business segment i.e. Pharmaceuticals.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,52,611.00
Capital work-in-progress 10,153.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 4,171.00
Intangible assets under development 3,497.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 6,20,350.00
Trade receivables, non-current 0.00
Loans, non-current 1,004.00
Other non-current financial assets
1 Other non - current financial assets 45,929.00
Total of other non-current financial assets 45,929.00
Total non-current financial assets 6,67,283.00
Deferred tax assets (net) 1,39,798.00
Other non-current assets
1 Other non-current assets 15,942.00
Total of other non-current assets 15,942.00
Total non-current assets 9,93,455.00
2 Current assets
Inventories 1,76,106.00
Current financial asset
Current investments 46,591.00
Trade receivables, current 2,06,233.00
Cash and cash equivalents 5,859.00
Bank balance other than cash and cash equivalents 206.00
Loans, current 182.00
Other current financial assets
Total of other current financial assets 3,28,149.00
Total current financial assets 5,87,220.00
Current tax assets (net) 3,239.00
Other current assets
1 Other current assets 70,938.00
Total of other current assets 70,938.00
Total current assets 8,37,503.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 18,30,958.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,391.00
Other equity 15,18,263.00
Total equity attributable to owners of parent 15,20,654.00
Non controlling interest
Total equity 15,20,654.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 19,688.00
Total of other non-current financial liabilities 19,688.00
Total non-current financial liabilities 19,688.00
Provisions, non-current 34,691.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 1,535.00
Total of other non-current liabilities 1,535.00
Total non-current liabilities 55,914.00
Current liabilities
Current financial liabilities
Borrowings, current 14,054.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 7,818.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,39,510.00
Total Trade payable 1,47,328.00
Other current financial liabilities
1 Other current financial liabilities 48,308.00
Total of other current financial liabilities 48,308.00
Total current financial liabilities 2,09,690.00
Other current liabilities 9,104.00
1 Other current liabilities 9,104.00
Total of other current liabilities 9,104.00
Provisions, current 18,472.00
Current tax liabilities (Net) 17,124.00
Deferred government grants, Current 0.00
Total current liabilities 2,54,390.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,10,304.00
Total equity and liabilites 18,30,958.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 341.00 683.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss (86.00) (172.00)
5 Total Other comprehensive income (255.00) (511.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,87,357.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 3,223.00
Adjustments for decrease (increase) in inventories (12,930.00)
Adjustments for decrease (increase) in trade receivables, current (50,785.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 159.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 6,033.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 11,579.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 586.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 511.00
Adjustments for dividend income 564.00
Adjustments for interest income 17,844.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 162.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (2,434.00)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (62,304.00)
Net cash flows from (used in) operations 1,25,053.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 28,638.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 96,415.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 194.00
Purchase of property, plant and equipment 9,780.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 2,79,027.00
Purchase of other long-term assets 3,27,014.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 564.00
Interest received 14,519.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 294.00
Net cash flows from (used in) investing activities (42,196.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 31,905.00
Payments of lease liabilities 1,368.00
Dividends paid 11,957.00
Interest paid 1,708.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (46,938.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 7,281.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 7,281.00
Cash and cash equivalents cash flow statement at beginning of period (15,291.00)
Cash and cash equivalents cash flow statement at end of period (8,010.00)





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 S&B Pharma LLC The Pharma Network LLC Subsidiary Sale of goods or services Not Applicable 3,597.50 484.00 546.90
2 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Sale of goods or services 2,500.00 Approved by the audit committee of the entity 25.30 0.00 117.60
3 Alkem Laboratories Limited Ascend GmbH Subsidiary Sale of goods or services 30,000.00 Approved by the audit committee of the entity 12,959.10 8,143.40 11,040.50
4 Alkem Laboratories Limited Ascend Laboratories (Pty) Ltd Subsidiary Sale of goods or services 6,000.00 Approved by the audit committee of the entity 1,171.00 445.90 1,024.80
5 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Sale of goods or services 12,500.00 Approved by the audit committee of the entity 2,842.90 1,772.40 1,984.30
6 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Sale of goods or services 12,500.00 Approved by the audit committee of the entity 6,635.10 3,850.90 6,284.00
7 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Sale of goods or services 35,000.00 Approved by the audit committee of the entity 8,709.40 8,318.80 7,809.80
8 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Sale of goods or services 5,000.00 Approved by the audit committee of the entity 678.00 1,591.50 2,440.60
9 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Sale of goods or services 2,70,000.00 Approved by the audit committee of the entity 96,385.80 63,414.60 85,683.90
10 Alkem Laboratories Limited Pharmacor Limited Subsidiary Sale of goods or services 2,500.00 Approved by the audit committee of the entity 1,225.70 1,036.30 1,631.80
11 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Sale of goods or services 35,000.00 Approved by the audit committee of the entity 10,269.80 6,973.20 11,656.30
12 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Sale of goods or services 5,000.00 Approved by the audit committee of the entity 1,506.00 7,197.10 9,277.10
13 Ascend Laboratories, SpA Pharma Network SpA Subsidiary Sale of goods or services Not Applicable 4,195.20 403.50 1,548.90
14 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity 0.20 1,028.10 1,243.90
15 Indchemie Health Specialities Private Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Sale of goods or services Not Applicable 176.00 195.70 70.20
16 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Sale of goods or services 1,000.00 Approved by the audit committee of the entity 7.30 170.00 41.50
17 Ascend Laboratories, SpA Pharmacor SPA Fellow Subsidiary Company Sale of goods or services Not Applicable 6,541.50 4,096.10 4,679.90
18 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Sale of goods or services 40,000.00 Approved by the audit committee of the entity 5,534.70 13,175.60 6,529.00
19 Alkem Laboratories Limited Ascend Laboratories Limited Subsidiary Sale of goods or services 3,500.00 Approved by the audit committee of the entity 29.20 0.00 99.10
20 Alkem Wellness Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Purchase of goods or services 25,000.00 Approved by the audit committee of the entity 6,119.70 2,871.40 2,864.70
21 Enzene Biosciences Limited Enzene Inc Subsidiary Sale of goods or services Not Applicable 18.10 0.00 0.00
22 Occlutech GmbH Occlutech France SARL Fellow Subsidiary Company Sale of goods or services Not Applicable 788.80 0.00 298.20
23 Occlutech GmbH Occlutech Italia S.r.l. Fellow Subsidiary Company Sale of goods or services Not Applicable 70.00 0.00 70.00
24 Occlutech GmbH Occlutech T?bbi �r�nler Sanayi ve Ticaret Limited ?irketi Fellow Subsidiary Company Sale of goods or services Not Applicable 45.50 0.00 78.30
25 Occlutech T?bbi �r�nler Sanayi ve Ticaret Limited ?irketi Occlutech GmbH Fellow Subsidiary Company Sale of goods or services Not Applicable 279.30 0.00 1,473.90
26 Occlutech GmbH Occlutech (UK) Ltd Fellow Subsidiary Company Sale of goods or services Not Applicable 141.90 0.00 48.80
27 Occlutech GmbH Occlutech International AB Fellow Subsidiary Company Sale of goods or services Not Applicable 910.40 0.00 2,931.90
28 Occlutech International AB Occlutech GmbH Fellow Subsidiary Company Sale of goods or services Not Applicable 2,035.40 0.00 16,543.50
29 Occlutech International AB Occlutech Italia S.r.l. Fellow Subsidiary Company Sale of goods or services Not Applicable 312.00 0.00 83.70
30 Occlutech T?bbi �r�nler Sanayi ve Ticaret Limited ?irketi Occlutech International AB Fellow Subsidiary Company Sale of goods or services Not Applicable 271.70 0.00 337.30
31 Occlutech International AB Occlutech (UK) Ltd Fellow Subsidiary Company Sale of goods or services Not Applicable 324.70 0.00 45.90
32 Occlutech International AB Occlutech France SARL Fellow Subsidiary Company Sale of goods or services Not Applicable (77.20) 0.00 77.20
33 Alkem Wellness Limited Indchemie Health Specialities Private Limited Fellow Subsidiary Company Purchase of goods or services 5,000.00 Approved by the audit committee of the entity 4.80 0.00 0.00
34 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Purchase of goods or services 20,000.00 Approved by the audit committee of the entity 315.90 178.30 133.40
35 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Purchase of goods or services 15,000.00 Approved by the audit committee of the entity 2,978.20 1,028.10 1,243.90
36 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Purchase of goods or services 30,000.00 Approved by the audit committee of the entity 9,955.30 4,962.00 3,482.80
37 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Purchase of goods or services 10,000.00 Approved by the audit committee of the entity 248.70 0.00 34.90
38 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Purchase of goods or services 5,000.00 Approved by the audit committee of the entity 3,404.50 412.50 1,972.40
39 Alkem Wellness Limited Indchemie Health Specialities Private Limited Fellow Subsidiary Company Sale of goods or services 3,000.00 Not Applicable 0.10 0.00 0.00
40 Enzene Biosciences Limited Enzene Inc Subsidiary Loan Approved by the audit committee of the entity 0.00 38,156.00 8,790.40
41 Ascend laboratories, LLC S&B Pharma , LLC Subsidiary Advance Not Applicable 3,993.70 0.00 3,993.70
42 Enzene Biosciences Limited Enzene Inc Subsidiary Investment 4,357.00 Approved by the audit committee of the entity 4,357.00 37,270.20 41,627.20 Investment 0 NA Unsecured Business requirement Textual Information(1)
43 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Investment 4,500.00 Approved by the audit committee of the entity 4,500.00 2,520.00 7,020.00 Investment 0 NA Unsecured Business requirement Textual Information(2)
44 Alkem Medtech Private Limited Occlutech Holding AG Subsidiary Investment 1,07,976.10 Approved by the audit committee of the entity 1,07,976.10 0.00 1,07,976.10 Investment 0 NA Unsecured Business requirement Textual Information(3)
45 Alkem Laboratories Limited Alkem Pharmaceuticals Scientific Office FZ LLC Subsidiary Investment 963.00 Approved by the audit committee of the entity 963.00 0.00 963.00 Investment 0 NA Unsecured Business requirement Textual Information(4)
46 Alkem Laboratories Limited Alkem Laboratories Korea Inc. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 0.60 25.40 26.30
47 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 0.50 12.20 15.50
48 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Interest received As per approval of Board of Directors or Shareholders of the entity as necessary 27.50 948.00 984.90
49 Enzene Biosciences Limited Enzene Inc Subsidiary Interest received Approved by the audit committee of the entity 1,246.10 0.00 8,790.40
50 Occlutech Holding AG Occlutech AG Subsidiary Interest received Not Applicable 419.20 0.00 0.00
51 Occlutech AG Occlutech GmbH Subsidiary Interest received Not Applicable 168.60 0.00 5,017.40
52 Alkem Laboratories Limited Mr Aniruddha Singh Relative of Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 24.60 0.00 0.00
53 Alkem Laboratories Limited Mr Basudeo Narain Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 1,281.40 0.00 0.00
54 Alkem Laboratories Limited Mr Manish Narang Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 128.00 0.00 0.00
55 Alkem Laboratories Limited Mr Mritunjay Kumar Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 763.00 0.00 0.00
56 Alkem Laboratories Limited Mr Nitin Agrawal Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 247.30 0.00 0.00
57 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 721.80 0.00 0.00
58 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 369.20 0.00 0.00
59 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 295.00 0.00 0.00
60 Alkem Laboratories Limited Mr Satish Kumar Singh Relatives of Key Managerial Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 437.50 0.00 0.00
61 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 635.70 0.00 0.00
62 Alkem Laboratories Limited Dr Vikas Gupta Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 965.60 0.00 0.00
63 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Remuneration As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary 693.80 0.00 0.00
64 The Pharma Network LLC Mr. Sandeep Singh Key Management Personnel Remuneration As per approval of Board of Directors. 417.10 0.00 0.00
65 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Dividend received 53.30 As per approval of Board of Directors or Shareholders of the entity as necessary 53.30 0.00 0.00
66 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Dividend received 510.00 As per approval of Board of Directors or Shareholders of the entity as necessary 510.00 0.00 0.00
67 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Business Support service 1,000.00 Approved by the audit committee of the entity 161.60 0.00 3,333.70
68 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Business Support service 1,500.00 Approved by the audit committee of the entity 12.50 17.00 42.20
69 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Business Support service 4,000.00 Approved by the audit committee of the entity 2,053.50 13,175.60 6,529.00
70 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Any other transaction Business Support service 200.00 Approved by the audit committee of the entity 54.20 78.00 187.60
71 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Subsidiary Any other transaction Business Support service Not Applicable 678.30 1,522.00 2,312.50
72 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Collection on behalf of Alkem Laboratories Ltd by Pharmacor Pty Ltd 4,632.10 Approved by the audit committee of the entity 4,632.10 0.00 4,632.10
73 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Collection on behalf of Alkem Wellness by Alkem Laboratories Ltd 30,000.00 Approved by the audit committee of the entity 2,062.00 0.00 0.00
74 Alkem Laboratories Limited Dr Meghna Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 50.00 Approved by the audit committee of the entity 15.00 0.00 0.00
75 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Consultancy fees 100.00 Approved by the audit committee of the entity 5.00 0.00 0.00
76 Alkem Laboratories Limited Alkem Foundation Subsidiary Any other transaction Donations given 4,500.00 Approved by the audit committee of the entity 1,313.90 0.00 0.00
77 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Investment 1,10,000.00 As per approval of Board of Directors. 1,10,000.00 45,000.00 1,55,000.00
78 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Guarantee Commission 100.00 Approved by the audit committee of the entity 1.30 0.00 1,984.40
79 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 0.00 0.00 0.00
80 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.10 0.00 0.00
81 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Guarantee commission 200.00 Approved by the audit committee of the entity 23.20 0.00 7,809.80
82 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 2.10 0.00 0.00
83 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 8.20 12.20 32.90
84 Alkem Laboratories Limited Pharmacor Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 1.10 0.00 0.00
85 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 2.50 0.00 0.00
86 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 2.50 0.00 0.00
87 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Guarantee commission 700.00 Approved by the audit committee of the entity 53.10 0.00 0.00
88 Enzene Biosciences Limited Enzene Inc Subsidiary Any other transaction Guarantee commission Not Applicable 10.10 0.00 0.00
89 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Guarantee commission 200.00 Approved by the audit committee of the entity 35.30 0.00 0.00
90 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Guarantee commission 600.00 Approved by the audit committee of the entity 7.10 0.00 0.00
91 Alkem Laboratories Limited Pharmacor SPA Step down subsidiary Any other transaction Guarantee commission 100.00 Approved by the audit committee of the entity 3.50 1.90 5.40
92 Alkem Laboratories Limited Alkem Laboratories Corporation Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 11.50 7.80 117.60
93 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 48.40 8,318.80 7,809.80
94 Alkem Laboratories Limited Pharma Network SpA Step down subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 11.60 12.20 32.90
95 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 9.00 6,973.20 11,656.30
96 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Any other transaction Reimbursement of Expenses by party 500.00 Approved by the audit committee of the entity 0.00 98.70 99.90
97 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 84.90 0.00 0.00
98 Alkem Laboratories Limited Mr. Sandeep Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 99.20 0.00 0.00
99 Alkem Laboratories Limited Mr Sarandhar Singh Relatives of Key Managerial Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 19.10 0.00 0.00
100 Alkem Laboratories Limited Mr Srinivas Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 154.70 0.00 0.00
101 Alkem Laboratories Limited Mr Basudeo Narain Singh Key Management Personnel Any other transaction Reimbursement of Expenses by party Not Applicable 2.20 0.00 0.00
102 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Reimbursement of Expenses by party 2,000.00 Approved by the audit committee of the entity 98.80 0.00 0.00
103 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Reimbursement of expenses by party 8,000.00 Approved by the audit committee of the entity 280.60 4,962.00 998.80
104 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of Expenses by party 2,500.00 Approved by the audit committee of the entity 824.70 2,297.20 3,333.70
105 Alkem Laboratories Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Step down subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 26.20 0.00 30.50
106 Alkem Laboratories Limited Alixer Nexgen Therapeutics Limited Subsidiary Any other transaction Reimbursement of expenses by party 10,000.00 Approved by the audit committee of the entity 7.50 575.70 42.60
107 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of Expenses by party 7,000.00 Approved by the audit committee of the entity 1,613.60 13,175.60 6,529.00
108 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Any other transaction Reimbursement of Expenses by party 100.00 Approved by the audit committee of the entity 50.10 0.00 0.00
109 The Pharma Network LLC S&B Pharma LLC Subsidiary Any other transaction Reimbursement of expenses by us Not Applicable 57.40 0.00 0.00
110 Pharmacor Pty Limited Alkem Laboratories Corporation Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 28.30 15.00 28.20
111 Alkem Laboratories Limited Ascend GmbH Subsidiary Any other transaction Reimbursement of expenses by us 2,000.00 Approved by the audit committee of the entity 207.70 205.10 409.60
112 Alkem Laboratories Limited Ascend Laboratories (UK) Limited Subsidiary Any other transaction Reimbursement of expenses by us 1,000.00 Approved by the audit committee of the entity 574.50 200.70 779.00
113 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Reimbursement of expenses by us 100.00 Approved by the audit committee of the entity 26.20 103.90 131.20
114 Alkem Laboratories Limited Ascend Laboratories SDN BHD. Subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 4.10 3.60 7.80
115 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Reimbursement of Expenses by us 500.00 Approved by the audit committee of the entity 133.60 338.60 197.50
116 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Reimbursement of Expenses by us 5,000.00 Approved by the audit committee of the entity 165.50 3,640.90 3,845.60
117 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Reimbursement of Expenses by us 2,000.00 Approved by the audit committee of the entity 1,678.20 1,979.90 3,691.90
118 Alkem Laboratories Limited The Pharmanetwork LLP Subsidiary Any other transaction Reimbursement of expenses by us 200.00 Approved by the audit committee of the entity 77.50 287.50 369.50
119 Cachet Pharmaceuticals Private Limited Indchemie Health Specialities Private Limited Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 0.30 31.00 70.20
120 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 1,000.00 Approved by the audit committee of the entity 4.80 0.00 0.80
121 Alkem Laboratories Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Step down subsidiary Any other transaction Reimbursement of expenses by us 100.00 Approved by the audit committee of the entity 4.80 0.00 30.50
122 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Reimbursement of expenses by us 4,500.00 Approved by the audit committee of the entity 286.60 0.00 34.90
123 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Reimbursement of Expenses by us 100.00 Approved by the audit committee of the entity 0.80 0.00 1,243.90
124 Alkem Laboratories Limited Adroit Biomed Ltd Subsidiary Any other transaction Reimbursement of Expenses by us 200.00 Approved by the audit committee of the entity 1.30 0.00 0.00
125 Alkem Laboratories Limited Ascend Laboratories Limited Subsidiary Any other transaction Reimbursement of expenses by us 1,050.00 Approved by the audit committee of the entity 369.80 99.90 99.10
126 Pharmacor SPA Ascend Laboratories SpA Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 410.80 0.00 4,560.20
127 Occlutech US LLC Occlutech GmbH Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 1,402.70 0.00 1,025.90
128 Occlutech GmbH Occlutech US LLC Fellow Subsidiary Company Any other transaction Reimbursement of expenses by us Not Applicable 1,396.10 0.00 1,025.90
129 Alkem Laboratories Limited Mrs Madhurima Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 8.80 0.00 0.00
130 Alkem Laboratories Limited Mr Sarvesh Singh Key Management Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 2.60 0.00 0.00
131 Alkem Laboratories Limited Dr Divya Singh Relatives of Key Managerial Personnel Any other transaction Rent expenses 100.00 Approved by the audit committee of the entity 6.80 0.00 0.00
132 Indchemie Health Specialities Private Limited Mr Mritunjay Kumar Singh Key Management Personnel Any other transaction Rent expenses Not Applicable 0.60 0.00 0.00
133 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Rent Income 200.00 Approved by the audit committee of the entity 30.00 170.00 41.50
134 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Rent Income 400.00 Approved by the audit committee of the entity 110.40 1,028.10 1,243.90
135 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Rent Income 100.00 Approved by the audit committee of the entity 0.60 0.00 0.00
136 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Rent Income 1,000.00 Approved by the audit committee of the entity 105.80 13,172.60 6,529.00
137 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Royalty expenses 3.00 Approved by the audit committee of the entity 1.20 178.30 133.40
138 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Royalty income 1,500.00 Approved by the audit committee of the entity 376.30 63,414.60 85,683.90
139 Alkem Laboratories Limited Enzene Biosciences Limited Subsidiary Any other transaction Royalty income 2,000.00 Approved by the audit committee of the entity 458.00 4,962.00 998.80
140 Alkem Laboratories Limited Alkem Medtech Private Limited Subsidiary Any other transaction Royalty income 100.00 Approved by the audit committee of the entity 3.90 0.00 0.00
141 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Royalty income 1,000.00 Approved by the audit committee of the entity 236.80 13,175.60 6,529.00
142 Alkem Medtech Private Limited Alkem MedTech Ortho Pvt Ltd (formerly known as Bombay Ortho Industries Pvt. Ltd.) Subsidiary Any other transaction Royalty income Not Applicable 7.90 1,522.00 2,312.50
143 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Inter-corporate deposit Not Applicable 0.00 50.10 50.10
144 Alkem Laboratories Limited Cachet Pharmaceuticals Private Limited Subsidiary Any other transaction Services received 1,000.00 Approved by the audit committee of the entity 8.40 178.30 133.40
145 Alkem Laboratories Limited Indchemie Health Specialities Private Limited Subsidiary Any other transaction Services received 2,000.00 Approved by the audit committee of the entity 124.20 1,028.10 1,243.90
146 Alkem Laboratories Limited Ascend Laboratories SAS Subsidiary Any other transaction Services rendered 1,000.00 Approved by the audit committee of the entity 70.40 3,850.90 6,284.00
147 Alkem Laboratories Limited Ascend Laboratories SpA Subsidiary Any other transaction Services rendered 500.00 Approved by the audit committee of the entity 161.10 8,318.80 7,809.80
148 Alkem Laboratories Limited Ascend Laboratories LLC Step down subsidiary Any other transaction Services rendered 2,500.00 Approved by the audit committee of the entity 476.00 63,414.60 85,683.90
149 Alkem Laboratories Limited Pharmacor Pty Limited Subsidiary Any other transaction Services rendered 200.00 Approved by the audit committee of the entity 35.80 6,973.20 11,656.30
150 Alkem Laboratories Limited Alkem Wellness Limited Subsidiary Any other transaction Services rendered 10,000.00 Approved by the audit committee of the entity 269.40 13,175.60 6,529.00
151 Alkem Wellness Limited Indchemie Health Specialities Private Limited Fellow Subsidiary Company Any other transaction Services received 10,000.00 Approved by the audit committee of the entity 1,545.40 311.60 194.20
152 Alkem Wellness Limited Cachet Pharmaceuticals Private Limited Fellow Subsidiary Company Any other transaction Services received 2,000.00 Approved by the audit committee of the entity 104.00 2,871.40 2,864.70
153 Enzene Biosciences Limited Alixer Nexgen Therapeutics Limited Fellow Subsidiary Company Any other transaction Services rendered Not Applicable 77.40 0.00 77.40
154 Indchemie Health Specialities Private Limited Mr R L Shenoy Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 2.20 0.00 0.00
155 Enzene Biosciences Limited Ms. Sangeeta Singh Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 1.40 0.00 0.00
156 Enzene Biosciences Limited Mr Narendra Kumar Aneja Key Management Personnel Any other transaction Sitting fees As per approval of Board of Directors or Shareholders of the entity as necessary 1.40 0.00 0.00
157 Alkem Laboratories Limited Mr Rajeev Kher Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 18.00 0.00 0.00
158 Alkem Laboratories Limited Mr Narendra Kumar Aneja Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 18.00 0.00 0.00
159 Alkem Laboratories Limited Mr R L Shenoy Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 19.00 0.00 0.00
160 Alkem Laboratories Limited Ms Neela Bhattacherjee Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 17.50 0.00 0.00
161 Alkem Laboratories Limited Mr Diwakar Gupta Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 18.50 0.00 0.00
162 Alkem Laboratories Limited Mr Sujjain Talwar Key Management Personnel Any other transaction Sitting fees and commission As per approval of Board of Directors or Shareholders of the entity as necessary 17.50 0.00 0.00
163 Alkem Laboratories Limited Ascend Laboratories S.A. DE. CV Step down subsidiary Any other transaction Reimbursement of expenses by us 100.00 Approved by the audit committee of the entity 0.00 155.00 156.70
164 Alkem Laboratories Limited S&B Pharma LLC Step down subsidiary Any other transaction Reimbursement of expenses by us 500.00 Approved by the audit committee of the entity 0.00 158.30 159.90
165 Alkem Laboratories Limited Connect 2 Clinic Private Limited Subsidiary Any other transaction Reimbursement of expenses by us 100.00 Approved by the audit committee of the entity 0.00 220.50 12.00
Total value of transaction during the reporting period 4,57,480.70



Text Block

Textual Information(1) Equity Investment
Textual Information(2) Equity Investment
Textual Information(3) Equity Investment
Textual Information(4) Equity Investment